TrialHuman vaccines & immunotherapeutics2021

Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6® cell-line: a phase 1 randomized controlled trial in adults.

Isabel Leroux-Roels et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.